The NPs are actively targeted to human epidermal factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), using HER2-targeted trastuzumab (TmAb) and EGFR-targeted Panitumumab (PmAb) Fab fragments, to deliver the drug combination to BC cells (Scheme 1, Table 1) [11]. Here, ERBB2 is linked to breast cancer.